Exosome Therapy Shows Promise Against Multiple Sclerosis
Metformin-loaded stem cell exosomes rebalanced immune T cell subsets in patient blood samples in laboratory testing.
Updated on Nov. 4, 2026 in Stroke
Researchers tested metformin-loaded exosomes derived from human adipose-derived mesenchymal stem cells on immune cells from patients with relapsing-remitting multiple sclerosis. The combined treatment rapidly shifted CD4+ T cell subsets toward healthy control levels in vitro.
Why it matters
Metformin's rapid clearance and poor bioavailability have limited its clinical translation for relapsing-remitting multiple sclerosis. Stem cell exosomes may act as a delivery system that improves drug stability, offering a possible route around that barrier.
Flow cytometry of patient blood cells showed elevated IFN-γ+ and IL-17+ CD4+ T cells and reduced FoxP3+ CD25+ CD4+ T cells compared with healthy controls at baseline. Exo-Met rapidly restored regulatory T cell frequency within 24 hours and significantly reduced IFN-γ+ CD4+ T cells by 72 hours, though whether these effects translate to clinical benefit remains untested.
The details
The team isolated peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis and healthy controls, then treated them with exosomes, metformin, Exo-Met, or IFN-β. Exosomes alone produced only a partial immunomodulatory effect, while metformin alone reduced IFN-γ+ and IL-17+ CD4+ T cells at different time points.
Timeline
Frequencies of CD4+ T cell subsets were measured at 24 hours and again at 72 hours after treatment.
Health Landscape
Exosomes derived from mesenchymal stem cells are being explored as drug delivery vehicles to improve the stability of compounds with poor bioavailability. This work applies that approach to metformin, a drug whose clinical translation for relapsing-remitting multiple sclerosis has been limited by rapid clearance.
This research is at an early laboratory stage and does not change current treatment options for multiple sclerosis patients. Any future clinical use would require further preclinical and clinical investigation before it could affect daily care or access.
The takeaway
Laboratory results suggest that delivering metformin inside stem cell exosomes could help rebalance immune cells in multiple sclerosis, but the findings remain preliminary. Readers should treat this as early-stage research rather than a new treatment option.
Further reading
For more on neurological conditions affecting the nervous system, explore the Stroke section.
Source note: This article includes information reported by Nature.
